The current state of the art and future trends in RAS-targeted cancer therapies.

Bispecific dimeric single-chain antibody fragment constructs, so-called ‘diabodies’, have been engineered to recognize such MHC I–peptide complexes on KRAS -mutant cells and recruit T cells by simultaneously binding to CD3; these agents induced T cell-mediated cytotoxicity in vitro, with some anticancer activity observed in mouse models (although the effect did not reach statistical significance) 198 .

also in 111,027 other papers